Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment

Respirology

Volumn 18, Issue 5, 2013, Pages 820-826

  Kondoh, Yasuhiro ^a   Taniguchi, Hiroyuki ^a   Ogura, Takashi ^b   Johkoh, Takeshi ^c   Fujimoto, Kiminori ^d   Sumikawa, Hiromitsu ^e   Kataoka, Kensuke ^a   Baba, Tomohisa ^b   Colby, Thomas V ^g   Kitaichi, Masanori ^f  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^c Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^d KURUME UNIVERSITY HOSPITAL   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^g MAYO CLINIC   (United States)

Author keywords

high resolution computed tomography; honeycombing; idiopathic pulmonary fibrosis; usual interstitial pneumonia.

Indexed keywords

CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; PIRFENIDONE;

ADULT; AGED; ARTICLE; CHRONIC RESPIRATORY FAILURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HEART LEFT VENTRICLE FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG CANCER; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; THORAX RADIOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84879344669     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12082     Document Type: Article

References (18)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.
2. Raghu G. Collard H.R. Egan J.J. et al., An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management, Am. J. Respir. Crit. Care Med., 2011, 183, 788-824
3. Tsushima K, Sone S, Yoshikawa S, et al. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir. Med. 2010; 104: 1712-1721.
4. Medical Section of the American Lung Association. Standardization of spirometry: 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107-1136.
5. Hanamoto S, Ohsuji T, Tsuyuguchi I, et al. Prediction formulas for pulmonary function tests expressed in linear and exponential form for healthy Japanese adults. Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30: 2051-2060.
6. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
7. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-537.
8. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538-542.
9. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 543-548.
10. Ley B, Collard HR, King TE Jr,. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431-440.
11. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 92-99.
12. Pirfenidone Clinical Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 821-829.
13. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 948-955.
14. Ryu JH, Colby TV, Hartman TE, et al. Smoking related interstitial lung diseases: a concise review. Eur. Respir. J. 2001; 17: 122-132.
15. Idiopathic D, Safrin S, et al. Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005; 172: 488-493.
16. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am. J. Respir. Crit. Care Med. 2008; 177: 433-439.
17. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-975.
18. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 36: 1067-1072.